NABRIVA THERAPEUTICS PLC's ticker is and the CUSIP is G63637113. A total of 34 filers reported holding NABRIVA THERAPEUTICS PLC in Q4 2020. The put-call ratio across all filers is 0.48 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $145,000 | -12.1% | 795,938 | +102.1% | 0.00% | – |
| Q1 2022 | $165,000 | -41.5% | 393,794 | -16.4% | 0.00% | – |
| Q4 2021 | $282,000 | +8.9% | 471,300 | +116.3% | 0.00% | – |
| Q3 2021 | $259,000 | -77.9% | 217,885 | -74.9% | 0.00% | -100.0% |
| Q2 2021 | $1,174,000 | +521.2% | 869,390 | +665.3% | 0.00% | – |
| Q1 2021 | $189,000 | -77.2% | 113,601 | -66.8% | 0.00% | -100.0% |
| Q4 2020 | $829,000 | – | 342,360 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ABG Innovation Capital Partners III GP Ltd | 45,849 | $8,000 | 0.60% |
| Aisling Capital Management LP | 90,000 | $16,000 | 0.01% |
| Frazier Life Sciences Management, L.P. | 425,650 | $77,000 | 0.01% |
| Values First Advisors, Inc. | 43,728 | $8,000 | 0.01% |
| Virtu Financial LLC | 127,585 | $23,000 | 0.00% |
| CCG WEALTH MANAGEMENT, LLC | 10,000 | $2,000 | 0.00% |
| Running Point Capital Advisors, LLC | 10,000 | $2,000 | 0.00% |
| WELLS FARGO & COMPANY/MN | 125 | $0 | 0.00% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |
| GEODE CAPITAL MANAGEMENT, LLC | 42,738 | $7,000 | 0.00% |